Details of the Drug

General Information of Drug (ID: DMMQ8ZG)

Drug Name

Furosemide

Synonyms

Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1]
Edema	MG29	Approved	[2]
Renal hypoplasia	N.A.	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Diuretics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

330.74

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [4]
Bioavailability: The bioavailability of drug is 60-82% [3]
Clearance: The clearance of drug is 1.23 mL/min/kg [5]
Elimination: The kidneys are responsible for 85% of total furosemide total clearance, where about 43% of the drug undergoes renal excretion [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 4 hours (40 mg furosemide oral adminutesistration) [7]
Metabolism: The drug is metabolized via the kidney [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.91513 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.012% [9]
Vd: The volume of distribution (Vd) of drug is 0.181 L/kg [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hyperparathyroidism	Not Available	PTH1R	OTQF5ZAK	[10]
Renal failure	Not Available	LPL	OTTW0267	[10]
Renal failure	Not Available	VLDLR	OTZBTD8C	[10]
-----------

Chemical Identifiers

Formula: C12H11ClN2O5S
IUPAC Name: 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
Canonical SMILES: C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
InChI: InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
InChIKey: ZZUFCTLCJUWOSV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3440
ChEBI ID: CHEBI:47426
CAS Number: 54-31-9
DrugBank ID: DB00695
TTD ID: D0PQ3G
VARIDT ID: DR00258
INTEDE ID: DR0757
ACDINA ID: D00295

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Blocker	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[12]
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[13]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[16]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[17]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Regulation of Drug Effects	[18]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Gene/Protein Processing	[19]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[20]
HLA class I histocompatibility antigen, B alpha chain (HLA-B)	OTNXFWY2	HLAB_HUMAN	Gene/Protein Processing	[21]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Protein Interaction/Cellular Processes	[22]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Protein Interaction/Cellular Processes	[22]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Drug Response	[10]
Natriuretic peptides A (NPPA)	OTMQNTNX	ANF_HUMAN	Gene/Protein Processing	[23]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Furosemide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Chlorothiazide	DMLHESP	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Chlorothiazide.	Heart failure [BD10-BD1Z]	[24]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[24]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypokalemia by the combination of Furosemide and Digitoxin.	Heart failure [BD10-BD1Z]	[25]
-----------

Coadministration of a Drug Treating the Disease Different from Furosemide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Increased renal excretion of Furosemide caused by Cefuroxime.	Acute bronchitis [CA42]	[26]
Framycetin	DMF8DNE	Major	Increased risk of ototoxicity by the combination of Furosemide and Framycetin.	Alcoholic liver disease [DB94]	[27]
Cefamandole	DMNEXZF	Moderate	Increased renal excretion of Furosemide caused by Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[26]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Furosemide and Dronedarone.	Angina pectoris [BA40]	[28]
Salbutamol	DMN9CWF	Moderate	Increased risk of hypokalemia by the combination of Furosemide and Salbutamol.	Asthma [CA23]	[29]
Cefotetan	DM07TX3	Moderate	Increased renal excretion of Furosemide caused by Cefotetan.	Bacterial infection [1A00-1C4Z]	[26]
Kanamycin	DM2DMPO	Major	Increased risk of nephrotoxicity by the combination of Furosemide and Kanamycin.	Bacterial infection [1A00-1C4Z]	[27]
Ceftizoxime	DM3VOGS	Moderate	Increased renal excretion of Furosemide caused by Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[26]
Cefoperazone	DM53PV8	Moderate	Increased renal excretion of Furosemide caused by Cefoperazone.	Bacterial infection [1A00-1C4Z]	[26]
Cefprozil	DM7DSYP	Moderate	Increased renal excretion of Furosemide caused by Cefprozil.	Bacterial infection [1A00-1C4Z]	[26]
Ceftriaxone	DMCEW64	Moderate	Increased renal excretion of Furosemide caused by Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[26]
Streptomycin	DME1LQN	Major	Increased risk of nephrotoxicity by the combination of Furosemide and Streptomycin.	Bacterial infection [1A00-1C4Z]	[27]
Cefepime	DMHVWIK	Moderate	Increased renal excretion of Furosemide caused by Cefepime.	Bacterial infection [1A00-1C4Z]	[26]
Cefaclor	DMJXDGC	Moderate	Increased renal excretion of Furosemide caused by Cefaclor.	Bacterial infection [1A00-1C4Z]	[26]
Gentamicin	DMKINJO	Major	Increased risk of ototoxicity by the combination of Furosemide and Gentamicin.	Bacterial infection [1A00-1C4Z]	[27]
Cefadroxil	DMMC345	Moderate	Increased renal excretion of Furosemide caused by Cefadroxil.	Bacterial infection [1A00-1C4Z]	[26]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Furosemide and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[30]
Cefazolin	DMPDYFR	Moderate	Increased renal excretion of Furosemide caused by Cefazolin.	Bacterial infection [1A00-1C4Z]	[26]
Netilmicin	DMRD1QK	Major	Increased risk of ototoxicity by the combination of Furosemide and Netilmicin.	Bacterial infection [1A00-1C4Z]	[27]
Cefditoren	DMSUVM1	Moderate	Increased renal excretion of Furosemide caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[26]
Cefonicid	DMTX2BH	Moderate	Increased renal excretion of Furosemide caused by Cefonicid.	Bacterial infection [1A00-1C4Z]	[26]
Cefradine	DMUNSWV	Moderate	Increased renal excretion of Furosemide caused by Cefradine.	Bacterial infection [1A00-1C4Z]	[26]
Cefoxitin	DMY8NC4	Moderate	Increased renal excretion of Furosemide caused by Cefoxitin.	Bacterial infection [1A00-1C4Z]	[26]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Furosemide and Cariprazine.	Bipolar disorder [6A60]	[31]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of hypocalcemia by the combination of Furosemide and Etidronic acid.	Bone paget disease [FB85]	[32]
Risedronate	DM5FLTY	Moderate	Increased risk of hypocalcemia by the combination of Furosemide and Risedronate.	Bone paget disease [FB85]	[32]
Ceftibuten	DMWV2AG	Moderate	Increased renal excretion of Furosemide caused by Ceftibuten.	Bronchitis [CA20]	[26]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Furosemide when combined with Phenylbutazone.	Chronic pain [MG30]	[33]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Furosemide when combined with Ketoprofen.	Chronic pain [MG30]	[33]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Levomilnacipran.	Chronic pain [MG30]	[34]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Sertraline.	Depression [6A70-6A7Z]	[34]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Vilazodone.	Depression [6A70-6A7Z]	[34]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Paroxetine.	Depression [6A70-6A7Z]	[34]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Furosemide and Selegiline.	Depression [6A70-6A7Z]	[35]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Vortioxetine.	Depression [6A70-6A7Z]	[34]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Furosemide and Isocarboxazid.	Depression [6A70-6A7Z]	[35]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Milnacipran.	Depression [6A70-6A7Z]	[34]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Escitalopram.	Depression [6A70-6A7Z]	[34]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Furosemide and Tranylcypromine.	Depression [6A70-6A7Z]	[35]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Desvenlafaxine.	Depression [6A70-6A7Z]	[34]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Furosemide and OPC-34712.	Depression [6A70-6A7Z]	[31]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Furosemide and Phenelzine.	Depression [6A70-6A7Z]	[35]
Diazepam	DM08E9O	Moderate	Additive hypotensive effects by the combination of Furosemide and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[36]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[37]
Ethacrynic acid	DM60QMR	Major	Increased risk of ototoxicity by the combination of Furosemide and Ethacrynic acid.	Essential hypertension [BA00]	[38]
Nadolol	DMW6GVL	Moderate	Increased risk of hyperglycemia by the combination of Furosemide and Nadolol.	Essential hypertension [BA00]	[39]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Furosemide when combined with Mefenamic acid.	Female pelvic pain [GA34]	[33]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Furosemide and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[30]
Metipranolol	DMJMVKI	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Metipranolol.	Glaucoma [9C61]	[39]
Levobetaxolol	DMSREPX	Moderate	Increased risk of hypertriglyceridemia by the combination of Furosemide and Levobetaxolol.	Glaucoma [9C61]	[39]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hypertriglyceridemia by the combination of Furosemide and Levobunolol.	Glaucoma [9C61]	[39]
Etelcalcetide	DMHP9BL	Major	Increased risk of hypocalcemia by the combination of Furosemide and Etelcalcetide.	Hyper-parathyroidism [5A51]	[40]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Furosemide due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[40]
Acebutolol	DM0TI4U	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Acebutolol.	Hypertension [BA00-BA04]	[39]
Captopril	DM458UM	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Captopril.	Hypertension [BA00-BA04]	[41]
Penbutolol	DM4ES8F	Moderate	Increased risk of hyperglycemia by the combination of Furosemide and Penbutolol.	Hypertension [BA00-BA04]	[39]
Nebivolol	DM7F1PA	Moderate	Increased risk of hypertriglyceridemia by the combination of Furosemide and Nebivolol.	Hypertension [BA00-BA04]	[39]
Pindolol	DMD2NV7	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Pindolol.	Hypertension [BA00-BA04]	[39]
Indapamide	DMGN1PW	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Indapamide.	Hypertension [BA00-BA04]	[24]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Trichlormethiazide.	Hypertension [BA00-BA04]	[24]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Furosemide and Perindopril.	Hypertension [BA00-BA04]	[41]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Furosemide and Quinapril.	Hypertension [BA00-BA04]	[41]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Furosemide and Lisinopril.	Hypertension [BA00-BA04]	[41]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[24]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Furosemide and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[42]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Furosemide when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[33]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Furosemide and Propiomazine.	Insomnia [7A00-7A0Z]	[31]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Furosemide and ITI-007.	Insomnia [7A00-7A0Z]	[31]
Ibandronate	DM0QZBN	Moderate	Increased risk of hypocalcemia by the combination of Furosemide and Ibandronate.	Low bone mass disorder [FB83]	[43]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Furosemide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[44]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Furosemide and Ozanimod.	Multiple sclerosis [8A40]	[35]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Furosemide and Promethazine.	Nausea/vomiting [MD90]	[31]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Furosemide and Sibutramine.	Obesity [5B80-5B81]	[34]
Polythiazide	DMCH80F	Moderate	Increased risk of fluid/electrolyte loss by the combination of Furosemide and Polythiazide.	Oedema [MG29]	[24]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Furosemide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[45]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Furosemide when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[33]
Carboplatin	DMG281S	Moderate	Increased risk of ototoxicity by the combination of Furosemide and Carboplatin.	Ovarian cancer [2C73]	[42]
Etodolac	DM6WJO9	Moderate	Antagonize the effect of Furosemide when combined with Etodolac.	Pain [MG30-MG3Z]	[33]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Furosemide when combined with Diflunisal.	Pain [MG30-MG3Z]	[33]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Furosemide when combined with Ibuprofen.	Pain [MG30-MG3Z]	[33]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Furosemide and Safinamide.	Parkinsonism [8A00]	[35]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Furosemide and Rasagiline.	Parkinsonism [8A00]	[35]
Esomeprazole	DM7BN0X	Moderate	Increased risk of hypomagnesemia by the combination of Furosemide and Esomeprazole.	Peptic ulcer [DA61]	[30]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Furosemide when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[33]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Furosemide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[31]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Furosemide when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[33]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Furosemide when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[33]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Furosemide when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[33]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Furosemide and Quetiapine.	Schizophrenia [6A20]	[31]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Mesoridazine.	Schizophrenia [6A20]	[42]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Furosemide and Aripiprazole.	Schizophrenia [6A20]	[31]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Iloperidone.	Schizophrenia [6A20]	[42]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Paliperidone.	Schizophrenia [6A20]	[42]
Perphenazine	DMA4MRX	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Perphenazine.	Schizophrenia [6A20]	[42]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Furosemide and Molindone.	Schizophrenia [6A20]	[31]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Furosemide and Thiothixene.	Schizophrenia [6A20]	[31]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Trifluoperazine.	Schizophrenia [6A20]	[42]
Risperidone	DMN6DXL	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Risperidone.	Schizophrenia [6A20]	[42]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Furosemide and Amisulpride.	Schizophrenia [6A20]	[42]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Furosemide and Asenapine.	Schizophrenia [6A20]	[31]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Furosemide and Pimozide.	Schizophrenia [6A20]	[46]
Cephapirin	DMV2JNY	Moderate	Increased renal excretion of Furosemide caused by Cephapirin.	Sepsis [1G40-1G41]	[26]
Plazomicin	DMKMBES	Major	Increased risk of nephrotoxicity by the combination of Furosemide and Plazomicin.	Urinary tract infection [GC08]	[27]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Furosemide and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[31]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Furosemide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[47]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Furosemide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[48]
-----------


⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrazine yellow	E00409	164825	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Furosemide 12.5 mg tablet	12.5 mg	Oral Tablet	Oral
Furosemide 20 mg tablet	20 mg	Oral Tablet	Oral
Furosemide 40 mg tablet	40 mg	Oral Tablet	Oral
Furosemide 50 mg tablet	50 mg	Oral Tablet	Oral
Furosemide 80 mg tablet	80 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4839).
2	Furosemide FDA Label
3	FDA Approved Drug Products: Retevmo (selpercatinib) capsules
4	BDDCS applied to over 900 drugs
5	Andreasen F, Mikkelsen E: Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. doi: 10.1007/bf00561400.
6	Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1:5S-12S.
7	Furosemide - FDA Label
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11	Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
12	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
13	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
14	Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009 Jan;61(1):47-54.
15	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
16	Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. Drug Metab Dispos. 2005 Apr;33(4):596-602. doi: 10.1124/dmd.104.002782. Epub 2005 Jan 7.
17	Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide. Clin Drug Investig. 2008;28(1):17-26. doi: 10.2165/00044011-200828010-00003.
18	Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
19	Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen. 2006 Oct;11(7):782-91.
20	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
21	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
22	Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens. 2006 May;24(5):915-22. doi: 10.1097/01.hjh.0000222762.84605.03.
23	[Effects of 4-hour erect posture and furosemide on the blood level of atrial natriuretic peptide in patients with primary arterial hypertension]. Przegl Lek. 1990;47(3):332-4.
24	Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
25	Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
26	Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
27	Athlin L, Domellof L, Holm S "Gentamicin treatment in severe surgical infections: serum levels, interactions, toxicity and efficacy." Acta Chir Scand 147 (1981): 225-30. [PMID: 7034430]
28	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
29	Lipworth BJ, McDevitt DG, Struthers AD "Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol." Am J Med 86 (1989): 653-7. [PMID: 2729315]
30	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
31	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
32	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
33	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
34	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
35	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
36	Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
37	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
38	Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981): 399-414. [PMID: 6973908]
39	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
40	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
42	Cerner Multum, Inc. "Australian Product Information.".
43	Product Information. Zometa (zoledronic acid). Novartis Pharmaceuticals, East Hanover, NJ.
44	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
45	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
46	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
47	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
48	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]